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TESTICULAR CARCINOMAS 
Incidence 
Testicular neoplasms are relatively rare with ap-
proximately two new cases per 100,000 male popu-
lation occurring per year. The peak occurrence is 
between the ages of 20 .and 40. Because of their 
highly malignant characteristics testicular neoplasms 
must be treated aggressively if cure is to be achieved. 
Etiology 
The most significant etiologic factor is the pre-
disposition for the occurrence of carcinoma in the 
cryptorchid or undescended testicle. The cryptorchid 
testis is at 40 to 50 times the risk of the normal scrotal 
testicle for developing a cancer; various theories for 
this predisposition to malignancy have been pro-
posed. The most likely is that the cryptorchid testicle 
is inherently abnormal (a very strong argument also 
to explain its failure to descend) and therefore pro-
vides a fertile ground for neoplastic change. 
Histology 
Testicular tumors may be divided into neo-
plasms of germ cell origin (arising from the spermato-
gonia within the seminiferous tubules) and of non-
germ cell origin (arising from the supporting Leydig 
and Sertoli cells). The latter constitute only 5% of all 
testicular tumors. 
For purposes of histology and treatment regi-
mens the germ cell tumors are divided into the semi-
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nomatous tumors which are most common, con-
stituting approximately 60% of all testicular tumors, 
and the non-seminomatous tumors constituting the 
remaining 35% of tumors. The non-seminomatous 
tumors consist of embryonal carcinoma, teratocarci-
noma, teratoma, or choriocarcinoma. Rarely do each 
of these types exist in absolutely pure form; most 
nonseminomatous tumors combine the elements of 
embryonal and teratomatous carcinomas and these 
may have elements of choriocarcinoma as well. With 
the exception of pure choriocarcinoma, a distinctly 
rare entity comprising less than 1 % of tumors, the 
treatment regimen for the nonseminomatous tumors 
is identical to and independent of the percentage of 
each histologic type that constitutes the mixed tumor. 
Diagnosis: 
All testicular masses must arouse suspicion of 
carcinoma and some swellings such as testicular he-
matomas, orchitis, and epididymitis may cause in-
duration difficult to distinguish from a tumor diag-
nosed only by inguinal exploration and biopsy. 
Treatment 
When a testicular mass is suspect of carcinoma, 
it must be explored through an inguinal incision. A 
rubbershod or umbilical tape is used to obstruct the 
venous return and therefore reduce or eliminate em-
bolic dissemination during manipulation of the tes-
ticle. If there is some doubt about the diagnosis, the 
testicle is isolated with towels, and a biopsy and a 
frozen section are performed prior to orchiectomy 
and removal of the cord. The testicle must never be 
biopsied through the scrotum, either by incision or by 
needle aspiration; by doing so an entirely new nodal 
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chain for metastases is established. The testicle drains 
to the para-aortic nodes, the scrotum to the inguinal 
nodes. If the tumor cells seed in the scrotal incision, 
which can easily occur, then the entire inguinal chain 
is at risk for embolic metastases. 
The diagnosis of testes tumors is too often de-
layed for a number of reasons. Routine and careful 
bi manual examination of the testes is often omitted in 
routine examinations. Furthermore, patients who 
note testicular masses are often reticent to present 
their complaints to a physician because of embarrass-
ment, or fear of association with venereal disease. 
Metastatic evaluation. Once a diagnosis is made 
a number of radiologic studies, serum studies, and 
urine studies are warranted to stage the neoplasm and 
identify areas of metastases. The chest represents a 
common area of distant metastases and should be 
evaluated not only by anteroposterior and lateral x-
ray, but by pulmonary tomograms. Lesions are fre-
quently bilateral and multiple. The primary route of 
drainage of the testicular lymphatics is to the para-
aortic and paracaval nodes between the superior mes-
enteric and the inferior mesenteric arteries. Cross-
over drainage does occur and is most frequent from 
the right side to the left. Bipedal lymphangiography is 
of importance in identifying spread to the retro-
peritoneal nodes . Para-aortic and paracaval nodes 
are well visualized as is, frequently, the supraclavicu-
lar node. Intravenous pyelogram also assesses the 
retroperitoneum by evaluation of renal and/ or 
ureteral deviation , compression, and deformity. 
Computerized axial tomography (CT) scanning and 
ultrasound studies can be used to delineate retro-
peritoneal masses precisely and may be used as 
noninvasive techniques to follow these masses peri-
odically during the course of chemotherapy or radio-
therapy to evaluate treatment. 
Staging of testes tumors is as follows: 
Stage A: Tumor limited to testes, that is, no me-
tastases . 
Stage B: Tumor present in testes with metastases 
limited to regional nodes, that is, para-
aortic nodes below diaphragm. 
Stage C: Tumor present in testes with metastases 
beyond regional nodes, that is, metas-
tases to scalene node, lung, bone, liver, 
and so forth . 
Seminomatous tumors. These neoplasms are 
characteristically very radiosensitive. Radiothera py 
constitutes the main method of treatment and rarely, 
if ever, is surgery indicated. If the tumor is Stage A 
(negative lymphangiogram and pulmonary tomo-
grams ), radiation is given in the dose of 2,500 R to 
the ipsilateral-iliac nodes and to the para-aortic 
nodes bilaterally to the level of the diaphragm. 
If the tumor is Stage B (evidence of nodal in-
volvement on lymphangiogram), the fields are ex-
tended so as to include the mediastinum and bqth 
supraclavicular areas, and the infradiaphragmatic 
area is treated to 3,000 R. The 5-year survival rate for 
patients with Stage A tumors, so treated, ranges 
around 95%. If the tumor is Stage B (evidence of 
positive para-aortic nodes), the 5-year survival rate 
will range around 80%. 
If the tumor is Stage C (evidence of pulmonary 
visceral or osseous metastases), radiation therapy 
may be given to these areas of metastatic involvement 
if they are relati vely isolated, that is, one or two 
pulmonary nodules in one lung lobe. If disease is 
more diffuse, however, a radiomimetic chemothera-
peutic agent, either chlorambucil (Leukeran) or cy-
clophosphamide (Cytoxan) is used . Five-year sur-
vival rates for Stage C tumors range between 40% and 
50%. 
The only indication for surgery for semi-
nomatous tumors arises with the failure of what has 
been diagnosed as seminoma to respond satisfactorily 
to radiotherapy. In such a case one must suspect the 
presence of non-seminomatous elements, and surgery 
with excisional biopsy will eliminate the lesion, con-
firm a change in histology, and dictate a change in 
treatment to that used for non-seminomatous neo-
plasms. 
Non-seminomatous tumors. There is significant 
controversy as to the optimal management of non-
seminomatous tumors with North American urologic 
centers applying surgery, and European centers em-
ploying radiation therapy as the primary modes of 
treatment of the retroperitoneal area . Non-semi-
nomatous tumors are much more difficult to con-
trol with radiation than the seminoma and there-
fore radiation failures are more common . 
In the United States a non-seminomatous neo-
plasm is approached as follows: if the tumor is Stage 
A, a retroperitoneal node dissection is undertaken; if 
lymph node dissection reveals no evidence of histo-
logic metastases to the nodes, no further treatment is 
undertaken; and if the nodes are positive, chemo-
therapy is administered as the tumor is pathologi-
cally Stage B. 
If the tumor is Stage B, a node dissection is again 
performed and chemotherapy instituted postopera-
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tively. If nodal dissection is incomplete or there is 
tumor spillage, radiotherapy postoperatively to the 
retroperitoneal area is recommended. Chemotherapy 
is administered for two years after the last evidence of 
clinical disease is noted. 
If the tumor is Stage C, chemotherapy is insti-
tuted and if clinically measurable metastatic disease 
regresses, a node dissection is then considered. 
Five-year survival rates for Stage A, non-semi-
nomatous tumors range from 85% to 90% (the pa-
thologist is not always 100% accurate and may have 
missed microfoci in the excised lymph nodes and/ or 
metastases may have skipped the retroperitoneal 
nodes and dissiminated distantly without nodal in-
volvement). Five-year survival rates for Stage B dis-
ease are 60% to 70% and for Stage C, 25% to 30%. 
Tumor markers. Until recently, 24-hour urinary 
choriogonadotropin was measured in patients with 
testicular tumor in an effort to identify those with 
choriocarcinoma which as a functioning cell would 
produce choriogonadotropins detectable in the urine. 
The assay used is a biological one and has all the 
inherent difficulties of bioassays. 
A serum radioimmunoassay has been developed 
to overcome this difficulty. It measures the B chain of 
human choriogonadotropin (termed Beta sub unit) 
and is very sensitive and specific. Any elevation in the 
male is abnormal and indicates the presence of func-
tioning tumor cells. 
Alpha-fetoprotein is a protein produced by the 
fetus, but its production ceases and levels fall to 
nanogram marks soon after birth. Testis carcinoma 
cells may revert to the metabolic machinery of the 
fetal cell and produce alpha-fetoprotein, causing in-
creased serum levels. Like the Beta sub unit, elevated 
alpha-fetoprotein identifies the presence of active tu-
mor. 
Tumor markers are sensitive indicators of resid-
ual microfoci of disease long before any evidence of 
clinical or radiologic disease may appear. Active che-
motherapy must continue until tumor markers are 
reduced to and remain within normal levels. 
CARCINOMA OF THE PROSTATE 
Incidence 
The incidence of carcinoma of the prostate is 
steadily increasing; at the present time it is the most 
common genitourinary malignancy and the second 
leading cause of death from cancer among males 
in the United States. Its incidence of 60 new cases/ 
100,000 population and 20 deaths/ 100,000 popula-
tion per annum is exceeded only by carcinoma of 
the lung. The incidence of carcinoma of the pros-
tate increases with age, and autopsy studies have 
revealed it in 50% to 80% of males who have survived 
to age 80. Thus, we can anticipate that with greater 
longevity the diagnosis of prostatic carcinoma will 
be made more frequently and the problems of 
treatment of a malignancy in an aged population 
will be of increasing concern. 
Etiology 
No specific carcinogen has been identified as the 
cause of prostate cancer. The most likely inciting 
event at present is a change in the hormonal milieu 
which occurs as a natural consequence of aging. The 
nature of the change and the hormone fluctuations 
involved are as yet unidentified. 
Anatomy and Histology 
The prostatic glandular elements can be divided 
into two major sectors-the inner periurethral glands 
and the peripheral tuboalveolar glands which are 
connected by long ducts to the prostatic urethra. The 
periurethral glands are those which most frequently 
give rise to benign hypertrophy and the peripheral 
tuboalveolar glands to adenocarcinoma of the pros-
tate. 
Natural History 
Carcinoma of the prostate is a neoplasm with 
varied growth characteristics and degrees of malig-
nancy. The tumor may be rapidly metastatic and 
cause death within one to two years or it may be 
slowly growing, metastasizing only five to ten, or 
even fifteen, years after discovery of the primary le-
sion; another five or more years may pass before the 
metastases become life-threatening. This variability 
makes it difficult to assess the efficacy of therapy, and 
makes it necessary to follow patients for ten to fifteen 
years after initiating treatment in order to judge its 
value. The reason for this is that, given a tumor with 
a relatively slow-growing and benign course, one can-
not state whether prolonged survival is based on the 
treatment administered or the low biologic potential 
of that tumor. Unfortunately, at the present time 
there are few characteristics, other than the grade of 
anaplasia, that can be measured to identify at the 
time of diagnosis which tumors will follow a benign 
course from those which will not. 
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Diagnosis 
While a high index of suspicion may be gener-
ated by induration felt on digital rectal examination, 
carcinoma of the prostate must be ultimately diag-
nosed by histologic proof of malignancy. A number 
of other causes for induration of the prostate include 
prostatic calculi, granulomatous prostatitis, nodular 
prostatic hypertrophy and, more rarely, tuberculous 
granulomas. Once a suspicious area of in duration or 
nodularity is identified a transperineal or transrectal 
needle biopsy employing the Vim-Silverman needle is 
used to obtain tissue for histologic examination. 
Other warning signals in the elderly male of 
prostatic cancer include the onset or recent ex-
acerbation of low back pain, possibly a reflection of 
osseous metastases; the presence of sciatic pain, pos-
sibly a reflection of sciatic nerve impingement by 
massive retroperitoneal lymphadenopathy secondary 
to metastases; and the rapid progression of bladder 
outlet obstruction which can be identical to that seen 
with benign prostatic hypertrophy (BPH). 
Radiographic identification of carcinoma of the 
prostate is facilitated by the characteristic radiodense 
or osteoblastic lesions most frequently found in the 
pelvic bones and the lumbosacral spine. These may 
be identified on routine skeletal survey, but more 
early identification is provided by the technetium 99 
phosphorous bone scan which identifies metastases 
prior to radiographic skeletal changes. (It has been 
shown that more than 50% of the bone must be 
destroyed or replaced by malignancy before a routine 
skeletal survey becomes positive). Intravenous pyelo-
graphy may demonstrate obstruction at the ure-
terovesical junction secondary to prostatic malignant 
growth and, specifically, involvement of the seminal 
vesicles. Also the ureters may be displaced by retro-
peritoneal metastatic adenopathy. 
Biochemical or serum abnormalities occur with 
prostatic carcinoma. Serum acid phosphatase repre-
sents- the most characteristic and distinct abnormal-
ity; in essence, it is a tumor marker. It can frequently 
be used to identify the presence of metastatic disease, 
and its levels may be followed as a means of mon-
itoring treatment; however, it is not a specific test as 
acid phosphatase may be elevated in a number of 
other diseases such as pulmonary embolism, muscle 
necrosis, Gaucher disease, and osteosarcoma, to 
mention a few. It is also not a very sensitive marker as 
diffuse metastases may be present in the face of a 
normal acid phosphatase. The recent development of 
a radioimmunoassay for measurement of prostatic 
acid phosphatase offers significant advantages for tu-
mor staging, and follow-up. The immune assay is 
specific for the prostatic fraction of acid phosphatase 
and is sensitive to extremely minor changes in serum 
levels of the enzyme. Elevation of alkaline phospha-
tase is a reflection of bony destruction and repair. 
Serum calcium may be elevated as a result of. exten-
sive osseous metastases. 
Treatment 
Many methods of treatment are used either indi-
vidually or in combination. Transurethral resection 
of the prostate is used to relieve obstruction. This is 
obviously palliative and relieves symptoms but does 
nothing to stem or alter the growth of the neoplasm. 
Radical prostatectomy, namely the total removal of 
the prostate gland and the seminal vesicles, is per-
formed with the intent to cure by removal of all 
neoplasm. Curative radiation therapy delivered from 
a linear accelerator or cobalt source is directed at the 
prostate and often the pelvic lymph nodes as well. 
Interstitial implantation of radioactive seeds is used 
in an effort to deliver high local doses. 
Treatment is based on the staging of the disease 
at the time of presentation: Stage A-carcinoma en-
tirely unsuspected on physical examination, or on 
serum chemical or radiographic examination but 
which is found incidentally on pathologic examina-
tion of the prostate excised for presumed BPH, that 
is, in the transurethrally resected prostatic chips or 
the prostate enucleated by an open technique. Stage 
B-tumor confined to the prostate gland on physical 
examination specifically without lateral or seminal 
vesicle extension; Stage C-tumor locally confined to 
the pelvis but demonstrating lateral extension and 
seminal vesicle invasion; Stage D-metastases to 
lymph nodes, bone, lung, and so forth. 
Management of Stage A depends to a large ex-
tent on the patient's age, the grade of lesion, and the 
extent of the involvement. When only microfoci of 
well differentiated neoplasm are present, it is reason-
able to pursue no further treatment. If the tumor is 
more extensive or poorly differentiated, treatment is 
as outlined for Stage B. 
For Stage B, either radical excision of the pros-
tate and seminal vesicles (radical prostatectomy) or 
treatment with external beam radiotherapy or inter-
stitial implantation of radioactive sources (1-125 
seeds) may be employed. The advantages of radio-
therapy are the inclusion of the periprostatic tissue 
(and thereby hoped-for sterilization of microscopic 
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extensions outside the prostate) and avoidance of the 
side effects of surgery, namely universal impotence 
and a I 0% to 20% incidence of incontinence. 
The survival rates for Stage 8 carcinoma of the 
prostate are approximately 75% at five years, 45% to 
50% at ten years, and 25% to 35% at fifteen years. 
In Stage C carcinoma of the prostate, extension 
beyond the confines of the prostate and seminal vesi-
cles usually makes cure by radical prostatectomy 
highly unlikely; therefore, radiation therapy , either 
external beam or interstitial seeds, constitutes the 
mainstay of treatment. Occasionally it is also neces-
sary to relieve prostatic obstruction by transurethral 
prostatectomy either before treatment or immedi-
ately afterwards. Five- and ten-year survival rates for 
Stage Care approximately 45% and 30% respectively. 
The philosophy for treatment of Stage D carci-
noma of the prostate varies throughout the country . 
It is our policy to await the appearance of symptoms 
prior to the institution of therapy. Cure of Stage D 
prostatic neoplasm has not been documented, and 
therefore palliation of symptoms, and prolongation 
of survival remain the primary objectives of treat-
ment. Conditions warranting treatment include sys-
temic symptoms such as weight Joss, fatigue, weak-
ness , bone pain, ureteral obstruction, and bone 
marrow replacement as evidenced by anemia. 
Hormonal manipulation (estrogen or or-
chiectomy) is the mainstay of treatment for meta-
static carcinoma of the prostate . Dramatic relief from 
pain and regression of metastases, and at times com-
plete disappearance of the primary prosta tic lesion, 
follow the administration of hormones, or castration. 
The administration of estrogens works via the nega-
tive feedback system whereby high-estrogen doses 
suppress luteinizing hormone (LH) and follicle-stim-
ulating hormone (FSH), both of which are pituitary 
trophic hormones stimulating the testes to produce 
testosterone . Orchiectomy removes the source of 
androgen production. It is felt at the present time that 
either one of these modes is equally effective and can 
be expected to produce regression in approximately 
80% of patients with prostate carcinoma. There is no 
documented advantage from using both methods, 
that is, estrogen plus orchiectomy as opposed to ei-
ther one or the other alone, nor unfortunately is a 
second regression seen with any frequency by apply-
ing one of these modes when a relapse occurs after 
the institution of the other. 
Estrogens have certain distinct disadvantages; an 
orally ingested pill is required daily , nausea can oc-
cur, as can gynecomastia and other secondary sex 
changes. Of greater significance is data demonstrat-
ing an increased incidence of death from cardiovascu-
lar disease, na mely fluid retention, pulmonary edema, 
and congestive heart failure in patients receiving es-
trogen therapy. Orchiectomy, a simple surgical pro-
cedure that can be performed under local anesthesia, 
avoids these secondary effects of estrogen treatment. 
Other forms of hormonal ablation include adre-
nalectomy and hypophysectomy, but these are rarely 
used and have not been consistently successful in 
offering extended palliation. 
Local radiation therapy to painful osseous le-
sions may significantly relieve discomfort. Radiation 
is reserved for treatment of well-localized areas of 
painful metastases. 
Cytotoxic agents have just come under investiga-
tion in clinical trials and hold some promise for treat-
ment of estrogen failures. Investigation of certain 
cytotoxic agents linked to hormones (Estracyst = 
estrogen + nitrogen mustard; Leo = prednisone + 
chlorambucil) suggests that cytotoxic agents may be 
delivered within the prostatic cancer cell by steroid 
carriers which attach to hormone receptors . Other 
agents which depend on the acid phosphatase enzyme 
for cleavage to the active form are also in develop-
mental stages . 
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